P
Pablo Tamayo
Researcher at University of California, San Diego
Publications - 185
Citations - 117545
Pablo Tamayo is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Cancer & Gene. The author has an hindex of 72, co-authored 177 publications receiving 97318 citations. Previous affiliations of Pablo Tamayo include University of California, Berkeley & Harvard University.
Papers
More filters
Journal ArticleDOI
Integrative Radiogenomic Profiling Identifies BRAF Mutations as Novel Radiotherapeutic Targets in Adenocarcinomas of the Lung
J.W. Hearn,B. Yard,Drew J. Adams,Pablo Tamayo,Stuart L. Schreiber,Matthew Meyerson,Peter S. Hammerman,Mohamed E. Abazeed +7 more
TL;DR: Tumor cells rather than endothelial cells are the critical targets that regulate primary tumor eradication by SBRT in primary mouse soft tissue sarcomas.
Proceedings ArticleDOI
Abstract 66: Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumors
Elizabeth S. McKenna,Pablo Tamayo,Yoon Jae Cho,E. Lorena Mora-Blanco,Courtney G. Sansam,Erik J. Tillman,Edward C. Koellhoffer,Scott L. Pomeroy,Charles W. M. Roberts +8 more
TL;DR: It is demonstrated that aberrant epigenetic silencing of the tumor suppressor gene BIN1 is a conserved event in SNF5-deficient cancers and contributes to tumorigenesis.
Journal ArticleDOI
Gene Expression Studies May Identify Lower Risk Myelodysplastic Syndrome Patients Likely to Respond to Therapy with Ezatiostat Hydrochloride (TLK199)
Naomi Galili,Pablo Tamayo,Olga B Botvinnik,Jill P. Mesirov,Jennifer Zikria,Gail L. Brown,Azra Raza +6 more
TL;DR: The expression data confirms that patients whose pre-therapy marrow shows under-expression of the JNK gene set are precisely those who benefit from this drug therapy and those patients who already over-express these genes are unlikely to respond.
Posted ContentDOI
STRIPAK directs PP2A activity toward MAP4K4 to promote oncogenic transformation
Jong Wook Kim,Christian Berrios,Miju Kim,Miju Kim,Amy E. Schade,Guillaume Adelmant,Huwate Yeerna,Emily Damato,Amanda Balboni Iniguez,Amanda Balboni Iniguez,Selene K. Swanson,Laurence Florens,Michael P. Washburn,Michael P. Washburn,Kim Stegmaier,Kim Stegmaier,Nathaniel Gray,Pablo Tamayo,Ole Gjoerup,Jarrod A. Marto,James A. DeCaprio,James A. DeCaprio,William C. Hahn,William C. Hahn,William C. Hahn +24 more
TL;DR: An unanticipated role of MAP4K4 is identified in transformation and the STRIPAK complex regulates PP2A specificity and activity and is found that STRN4, a member ofSTRIPAK, is associated with ST and is required for ST-PP2A-induced cell transformation.
Journal ArticleDOI
Immunotherapy treatment responses in hepatocellular carcinoma patients with nonalcoholic fatty liver disease cirrhosis.
Jeremy T.H. Chang,Joseph F. Ryan,Veeral Ajmera,Kathryn J. Fowler,Stephanie Ting,Pablo Tamayo,Adam M. Burgoyne +6 more
TL;DR: HCC patients with NAFLD cirrhosis experienced significantly higher rates of disease progression as the best response to anti-PD-1/PD-L1 therapies compared to HCC patients withoutNAFLD Cirrhosis, and the use of immunotherapy in the HCC population continues to expand.